Investigating the addition of oral HIV self-tests among populations with high testing coverage - Do they add value? Lessons from a study in Khayelitsha, South Africa.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 27 09 2018
accepted: 03 04 2019
entrez: 4 5 2019
pubmed: 3 5 2019
medline: 10 1 2020
Statut: epublish

Résumé

HIV self-testing (HIVST) offers a useful addition to HIV testing services and enables individuals to test privately. Despite recommendations to the contrary, repeat HIV testing is frequent among people already on anti-retroviral treatment (ART) and there are concerns that oral self-testing might lead to false negative results. A study was conducted in Khayelitsha, South Africa, to assess feasibility and uptake of HIVST and linkage-to-care following HIVST. Participants were recruited at two health facilities from 1 March 2016 to 31 March 2017. People under 18 years, or with self-reported previously-diagnosed HIV infection, were excluded. Participants received an OraQuick Rapid HIV-1/2 Antibody kit, and reported their HIVST results by pre-paid text message (SMS) or by returning to the facility. Those not reporting within 7 days were contacted by phone. Electronic and paper-based clinical and laboratory records were retrospectively examined for all participants to identify known HIV outcomes, after matching for name, date of birth, and sex. These findings were compared with self-reported HIVST results where available. Of 639 participants, 401 (62.8%) self-reported a negative HIVST result, 27 (4.2%) a positive result, and 211 (33.0%) did not report. The record search identified that of the 401 participants self-reporting a negative HIVST result, 19 (4.7%) were already known to be HIV positive; of the 27 self-reporting positive, 12 (44%) were known HIV positive. Overall, records showed 57/639 (8.9%) were HIV positive of whom 39/57 (68.4%) had previously-diagnosed infection and 18/57 (31.6%) newly-diagnosed infection. Of the 428 participants who self-reported a result, 366 (85.5%) reported by SMS. HIVST can improve HIV testing uptake and linkage to care. SMS is acceptable for reporting HIVST results but negative self-reports by participants may be unreliable. Use of HIVST by individuals on ART is frequent despite recommendations to the contrary and its implications need further consideration.

Identifiants

pubmed: 31048859
doi: 10.1371/journal.pone.0215454
pii: PONE-D-18-28147
pmc: PMC6497254
doi:

Substances chimiques

Anti-Retroviral Agents 0
HIV Antibodies 0
Reagent Kits, Diagnostic 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0215454

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Afr J AIDS Res. 2016;15(1):67-75
pubmed: 27002359
Int J STD AIDS. 2017 Nov;28(13):1341-1347
pubmed: 28449628
J Int AIDS Soc. 2017 Jan 01;19(1):21111
pubmed: 28406597
AIDS. 2006 Aug 1;20(12):1655-60
pubmed: 16868447
PLoS Med. 2015 Sep 08;12(9):e1001873
pubmed: 26348035
J Int AIDS Soc. 2017 May 15;20(1):21594
pubmed: 28530049
Syst Rev. 2016 Apr 05;5:52
pubmed: 27048500
Int J STD AIDS. 2017 Jun;28(7):702-707
pubmed: 27538723
PLoS One. 2016 Apr 04;11(4):e0152653
pubmed: 27044006
AIDS Behav. 2016 Nov;20(11):2629-2638
pubmed: 26781866
Lancet HIV. 2018 Jun;5(6):e277-e290
pubmed: 29703707
J Clin Microbiol. 2003 May;41(5):2153-5
pubmed: 12734265
AIDS. 2017 Jul 1;31 Suppl 3:S203-S212
pubmed: 28665878
PLoS Med. 2016 Nov 8;13(11):e1002166
pubmed: 27824882
BMC Med. 2016 Feb 19;14:34
pubmed: 26891969
J Int AIDS Soc. 2017 Aug 29;20(Suppl 6):21751
pubmed: 28872275
South Afr J HIV Med. 2017 Sep 22;18(1):775
pubmed: 29568643
Lancet HIV. 2016 Jun;3(6):e266-74
pubmed: 27240789
PLoS One. 2015 Apr 16;10(4):e0125187
pubmed: 25881059
AIDS. 2016 May 15;30(8):1287-94
pubmed: 26807967
BMC Public Health. 2013 Aug 08;13:735
pubmed: 23924387
AIDS Behav. 2014 Feb;18(2):254-62
pubmed: 23657758
J Int AIDS Soc. 2017 Jun 26;20(1):21610
pubmed: 28691442

Auteurs

Hazel Ann Moore (HA)

Médecins Sans Frontières, Khayelitsha Project, Cape Town, South Africa.

Carol A Metcalf (CA)

Médecins Sans Frontières, Khayelitsha Project, Cape Town, South Africa.

Tali Cassidy (T)

Médecins Sans Frontières, Khayelitsha Project, Cape Town, South Africa.
Division of Public Health Medicine, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Damian Hacking (D)

Médecins Sans Frontières, Khayelitsha Project, Cape Town, South Africa.

Amir Shroufi (A)

Médecins Sans Frontières, Cape Town, South Africa.

Sarah Jane Steele (SJ)

Médecins Sans Frontières, Cape Town, South Africa.

Laura Trivino Duran (LT)

Médecins Sans Frontières, Cape Town, South Africa.

Tom Ellman (T)

Southern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH